Rotta Research Laboratorium

Rottapharm Spa

Rotta Research Laboratories S.p.a.

Paolo Senin

Francesco Makovec

Luigi A Rovati

Lucio C Rovati

Ivo Setnikar

Antonio Giordani

Walter Peris

Angelo Luigi Rovati

Matteo Ghirri

Antonino Santoro

Rolando Chiste'

Paola Gilotta

Pierluigi Casula

Luigi Angelo Rovati

Elena Tacconi

Formulation for oral administration, in the form of tablets or of powder for extemporaneous use, able to exert a beneficial effect on the cardiovascular system and having eulipidaemic activity, cholesterol-lowering and triglyceride-lowering activity, antioxidant activity, and a protective action on the vasal endothelium, comprising berberine in combination with a policosanol and/or red yeast and preferably containing an antioxidant, such as astaxanthin and/or folic acid.

Formulation for oral administration with beneficial effects on the cardiovascular system

Described is a new crystalline Form A of Andolast disodium salt, triclinic, displaying a thermal event at 98-112&#xb0; C. and melting with decomposition at about 400&#xb0; C. (DSC). Andolast disodium Form A is a not hygroscopic solid, surprisingly stable to several humidity conditions in a temperature range acceptable for ordinary storage conditions. In addition its stability allows both chemical manufacturing and pharmaceutical manufacturing process consistency and reproducibility under conditions more viable and less expensive when compared to those used for highly hygroscopic solids.

Crystalline and stable form of andolast

A composition for the relief and/or prevention of climacteric and menopausal disorders affecting women in pre-, peri- or post-menopause, comprising Soy Isoflavones and viable lactic acid bacteria preferablysporogenes aimed to enhance the absorption of Soy Isoflavones, the composition being provided in dosage forms for oral administration. Preferably the composition also comprisesdry extract and a pharmaceutically acceptable calcium salt and/or Vitamin D.

Phytoestrogens and probiotic for women's health

A pharmaceutical composition comprising, as active ingredient, N-4-(1H-tetrazol-5-yl)phenyl-4-(1H-tetrazol-5-yl)benzamide disodium salt (CR 2039, Andolast) or another pharmaceutically-acceptable salt thereof and a flavoring, and optionally including a pharmaceutically-acceptable inert carrier and/or a pharmaceutically-acceptable sweetener, the composition being suitable for administration by oral inhalation.

Pharmaceutical composition for inhalation containing CR 2039 (Andolast)

New derivatives of D,L-glutamic acid and D,L-aspartic acid are described having the formulae: ##STR1## in which n is equal to 1 or 2, R.sub.1 is a phenyl group mono-, di- or tri-substituted with linear or branched C.sub.1 -C.sub.4 alkyl groups, which may be the same or different, or with halogens, with a cyano group or a trifluoromethyl group, and in which R.sub.2 is selected from the group consisting of morpholino, piperidino and amino with one or two linear, branched or cyclic alkyl group substituents containing from 1 to 8 carbon atoms, which may be the same or different, or a pharmaceutically-acceptable salt thereof. The compounds have an antagonistic activity towards bioactive polypeptides and are useful particularly in the treatment of illnesses of the digestive system and the central nervous system, as pain killers, and for the treatment of anorexia and all those affections (for example tumours) in which exogenous or endogenous bioactive polypeptides are involved.

Derivatives of glutamic acid and aspartic acid

The compound consists of a mixed salt of glucosamine sulphate and sodium chloride corresponding to the formula: ##STR1## and is in the form of a crystalline powder with a melting point above 300.degree. C. The salt is stable at ambient temperatures and humidities and has pharmacological properties practically identical to those of glucosamine sulphate.

Stable compounds of glucosamine sulphate

The subject of the invention is a new use of D,L-4-benzamido-N,N-dipropyl-glutaramic acid (proglumide) in human pain relief. According to the invention proglumide is used both alone, at dosages of from 0.5 to 30 mg/kg of body weight, and in association with analgesic-narcotic drugs, it being able to potentiate the analgesic activity of these drugs.

Proglumide, pharmaceutical preparations and compositions including it

Compounds having the general formula: ##STR1## in which: Ad is 1-adamantyl (C.sub.10 H.sub.15) radical

Quaternary ammonium derivatives of adamantane with antimicrobic activity

5-nitro-imidazole derivatives of the formula ##STR1## in which R.sub.1 is hydrogen, methyl, ethyl or phenyl, n is 2 or 3, and R.sub.2 is methyl, ethyl, carboxymethyl or carboxyethyl, and the pharamceutically acceptable acid addition salts thereof, useful as antiprotozoics.

5-Nitro-imidazole with antiprotozoic activity

Tyrosine derivatives of the formula: ##STR1## wherein: R.sub.1 is a linear or branched-chain alkyl group having 1-6 carbon atoms, terminating by a tertiary amino group; R.sub. 2 is an unsubstituted, monosubstituted or di-substituted phenyl or benzyloxy group, the substituent being --Cl, --Br, --NO.sub.2, --OCH.sub.3, --CH.sub.3 or --CF.sub.3 ; R.sub.3 is a primary, secondary or tertiary amino group or an aryl-alkylamino group having 7-9 carbon atoms; and salts of said tyrosine derivatives with pharmaceutically acceptable acids.

O-Tertiary amino-alkyl-N-benzoyl tyrosil amides

Anti-inflammatory antirheumatic compounds of the formula: ##SPC1## Wherein n.sub.1 and n.sub.2 are each either 2 or 3, and wherein the two tertiary amino-groups may, if desired, be present in the form salified by a pharmaceutically acceptable acid such as oxalic, citric, maleic, fumaric or hydrochloric acid. The preferred compound is N'-2-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetoxy]-ethyl-N-3-(N -benzoyl-N',N'-di-n-propyl-DL-isoglutaminoyl)-oxypropyl-piperazine, preferably in the form of dimaleate.

Growing community of inventors

Monza, Italy

Paolo Senin